The Electronic Patient-Reported Outcome (ePRO) Consortium was established by the Critical Path Institute (C-Path) in 2011. Along with C-Path, the members of the ePRO Consortium are firms that provide electronic data collection technologies and services for capturing patient-reported outcome (PRO) and other clinical outcome assessment (COA) data in clinical trials.
The mission of the ePRO Consortium is to advance the science of clinical trial endpoint assessment by collaboratively supporting and conducting research, designing and delivering educational opportunities, and developing and disseminating best practice recommendations for electronic collection of clinical outcome data.
The ePRO Consortium provides a pre-competitive environment in which a critical mass of experts can collaborate to generate measurement equivalence data, develop specification documents and data standards, and provide guidance on methodological considerations related to ePRO applications. All of these activities are aimed at enhancing the quality, practicality, and acceptability of electronic capture of clinical trial endpoint data. The ePRO Consortium works closely with C-Path’s PRO Consortium to make the PRO instruments emerging from its therapeutic area working groups available in multiple data collection formats. The overarching aim is to enhance public health by optimizing the value of PRO data in medical product evaluation and clinical decision making.
C-Path’s role in the ePRO Consortium is to serve as a recognized and respected neutral third party that provides overall administrative support and oversight. C-Path provides a Director who is responsible for the overall management of the Consortium. The Director and her staff coordinate all projects and provide financial oversight, project management, and scientific oversight/consultation. Working with the ePRO Consortium participants, C-Path will facilitate the development and publication of scientific articles and supporting materials from the projects undertaken by the ePRO Consortium.